A Delluc, E Pasquier, L de Saint Martin, D Mottier. Rituximab’s cost for the treatment of primary cold agglutinin disease should not limit its use. Haematologica 2006;91(3):ECR05-ECR05; https://doi.org/10.3324/%x.
To create an adaptation, translation, or derivative of the
original work, for commercial e-prints and printed articles further permission is
required. For
information contact: marketing@haematologica.org
Other types of copyright management, can be agreed with the Editorial office.
